Continuous precipitation‐filtration process for initial capture of a monoclonal antibody product using a four‐stage countercurrent hollow fiber membrane washing step
Biotechnology and Bioengineering · 2024
DOI: 10.1002/bit.28525 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2024. Written by Mirko Minervini and 9 co-authors. Institution: Department of Chemical Engineering, The Pennsylvania State University, State College, Pennsylvania, USA. Major MEDLINE topics: Antibodies, Monoclonal, Cricetulus. Cited 29 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NIGMS NIH HHS, CESMII, National Institute for Innovation in Manufacturing Biopharmaceuticals.
Abstract (original language)
The significant increase in product titers, coupled with the growing focus on continuous bioprocessing, has renewed interest in using precipitation as a low‐cost alternative to Protein A chromatography for the primary capture of monoclonal antibody (mAb) products. In this work, a commercially relevant mAb was purified from clarified cell culture fluid using a tubular flow precipitation reactor with dewatering and washing provided by tangential flow microfiltration. The particle morphology was evaluated using an inline high‐resolution optical probe, providing quantitative data on the particle size distribution throughout the precipitation process. Data were obtained in both a lab‐built 2‐stage countercurrent washing system and a commercial countercurrent contacting skid that provided 4 stages of continuous washing. The processes were operated continuously for 2 h with overall mAb yield of 92 ± 3% and DNA removal of nearly 3 logs in the 4‐stage system. The high DNA clearance was achieved by selective redissolution of the mAb using a low pH acetate buffer. Host cell protein clearance was 0.59 ± 0.08 logs, comparable to that based on model predictions. The process mass intensity was slightly better than typical Protein A processes and could be significantly improved by preconcentration of the antibody feed material.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Chemical Engineering, The Pennsylvania State University, State College, Pennsylvania, USA.
- Department of Chemical and Biological Engineering, Rensselaer Polytechnic Institute, Troy, New York, USA.
- ChromaTan, Inc., Gwynedd, Pennsylvania, USA.
- Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
Funding
- NIGMS NIH HHS
- CESMII
- National Institute for Innovation in Manufacturing Biopharmaceuticals
- U.S. Department of Commerce, National Institute of Standards and Technology
- U.S. Department of Energy's Office of Energy Efficiency and Renewable Energy (EERE) under the Clean Energy Smart Manufacturing Innovation Institute (CESMII)
- National Institute of General Medical Sciences (NIGMS) Biomolecular Science and Engineering Training Program
Cite
APA
Minervini, M., Mergy, M., Zhu, Y., Gutierrez Diaz, M. A., Pointer, C., Shinkazh, O., Oppenheim, S. F., Cramer, S. M., Przybycien, T. M., & Zydney, A. L. (2024). Continuous precipitation‐filtration process for initial capture of a monoclonal antibody product using a four‐stage countercurrent hollow fiber membrane washing step. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28525
Vancouver
Minervini M, Mergy M, Zhu Y, Gutierrez Diaz MA, Pointer C, Shinkazh O, et al. Continuous precipitation‐filtration process for initial capture of a monoclonal antibody product using a four‐stage countercurrent hollow fiber membrane washing step. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28525
BibTeX
@article{Minervini2024,
author = {Minervini, Mirko and Mergy, Matthew and Zhu, Yuncan and Gutierrez Diaz, Mario A and Pointer, Craig and Shinkazh, Oleg and Oppenheim, Sheldon F and Cramer, Steven M and Przybycien, Todd M and Zydney, Andrew L},
title = {Continuous precipitation‐filtration process for initial capture of a monoclonal antibody product using a four‐stage countercurrent hollow fiber membrane washing step},
journal = {Biotechnology and Bioengineering},
year = {2024},
doi = {10.1002/bit.28525}
}
EUVIMED